India’s Glenmark Pharmaceuticals Ltd said it entered into an exclusive marketing agreement with Novartis Biosciences S.A, a subsidiary of Novartis AG, for three products meant for treating chronic obstructive pulmonary disease (COPD) in Brazil.
Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them.
Glenmark will be responsible for promoting, commercializing and distributing of these products in Brazil.
The agreement will be effective from July 01, 2019 onwards.
The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro, a combination of Indacaterol and Glycopyrronium, which are indicated for relief of symptoms in adults with COPD.
“This arrangement with a leading global pharmaceutical company will strengthen our respiratory franchise in Brazil,” said Glenmark.
It said the partnership is in line with the company’s plans to expand its respiratory product offerings in Brazil.